Oculis Holding AG (NASDAQ:OCSAW) Short Interest Update
by Amy Steele · The Cerbat GemOculis Holding AG (NASDAQ:OCSAW – Get Free Report) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 2 shares, a drop of 92.0% from the April 15th total of 25 shares. Based on an average trading volume of 510 shares, the days-to-cover ratio is presently 0.0 days.
Oculis Price Performance
Shares of OCSAW stock traded up $1.30 during trading hours on Monday, reaching $22.30. The stock had a trading volume of 200 shares, compared to its average volume of 3,581. The stock’s fifty day simple moving average is $15.94 and its 200 day simple moving average is $13.03. Oculis has a 12 month low of $4.85 and a 12 month high of $22.64.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.